USRE43586EExpiredUtilityPatentIndex 76
Antibodies to prostate-specific membrane antigen
Est. expiryNov 5, 2012(expired)· nominal 20-yr term from priority
G01N 2800/342C07K 16/3069C07K 14/4748C07K 14/705
76
PatentIndex Score
12
Cited by
558
References
33
Claims
Abstract
This invention provides purified antibodies to the outer membrane domain of prostate-specific membrane (PSM) antigen, compositions of matter comprising PSM antigen antibodies conjugated to a radioisotope or a toxin, and a method of imaging prostate cancer by using PSM antigen antibodies.
Claims
exact text as granted — not AI-modified1. A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35).
2. A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36).
3. A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).
4. A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure each of the following amino acid sequences:
(a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35); (b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); (c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37); and (d) Ala-Gly-Ala-Leu-Val-Leu-Ala-Gly-Gly-Phe-Phe-Leu-Leu-Gly-Phe-Leu-Phe (SEQ ID 80:38).
5. A purified monoclonal antibody which binds to a fragment of an outer membrane domain of prostate specific membrane antigen, which fragment has within its structure each of the following amino acid sequences:
(a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);
(b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); and
(c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).
6. A purified monoclonal antibody which binds to a fragment of prostate specific membrane antigen, which fragment corresponds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.
7. A purified monoclonal antibody which binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35).
8. A purified monoclonal antibody which binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36).
9. A purified monoclonal antibody which binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).
10. A purified monoclonal antibody which binds to an outer membrane domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.
11. A purified monoclonal antibody which binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.
12. The purified antibody of any one of claims 1 - 11 , wherein the antibody is a monoclonal antibody.
13. A composition of matter comprising the a monoclonal antibody of any one of 1 - 11 and an agent conjugated to the monoclonal antibody thereto, wherein the monoclonal antibody binds to an outer membrane domain of prostate-specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.
14. The composition of matter of claim 13 , wherein the agent is a radioisotope or toxin.
15. A composition comprising a carrier and the composition of matter of claim 13 .
16. A method of imaging prostate cancer in a subject which comprises administering to the subject the composition of matter of claim 13 , wherein the agent is an imaging agent under conditions permitting formation of a complex between the composition of matter and prostate specific membrane antigen, and obtaining an image of any complex so formed.
17. A monoclonal antibody having an antigen-binding region -specific for the extracellular domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.
18. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a fragment of an outer membrane domain of prostate-specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO:35).
19. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a fragment of an outer membrane domain of prostate-specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO:36).
20. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a fragment of an outer membrane domain of prostate-specific membrane antigen, which fragment has within its structure the consecutive amino acid sequence Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO:37).
21. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a fragment of an outer membrane domain of prostate-specific membrane antigen, which fragment has within its structure each of the following amino acid sequences: (a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35); (b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); and (c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).
22. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a fragment of prostate-specific membrane antigen, which fragment corresponds to a hydrophilic region of an outer membrane domain of prostate-specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.
23. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a hydrophilic region of an outer membrane domain of prostate-specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO:35).
24. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a hydrophilic region of an outer membrane domain of prostate-specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO:36).
25. A composition of comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a hydrophilic region of an outer membrane domain of prostate-specific membrane antigen, which hydrophilic region has within its structure the consecutive amino acid sequence Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO:37).
26. A composition of matter comprising a monoclonal antibody and an agent conjugated thereto, wherein the monoclonal antibody binds to a hydrophilic region of an outer membrane domain of prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.
27. The composition of matter of any of claim 18-20, or 21-26, wherein the agent is a radioisotope or toxin.
28. A composition comprising a carrier and the composition of matter of any of claim 18-20 or 21-26.
29. A method of imaging prostate cancer in a subject which comprises administering to the subject the composition of matter of any of claim 18-20 or 21-26, wherein the agent is an imaging agent, under conditions permitting formation of a complex between the composition of matter and prostate-specific membrane antigen, and obtaining an image of any complex so formed.
30. A composition comprising a carrier and the composition of matter of claim 27.
31. The composition of claim 30, wherein the agent is a radioisotope.
32. The composition of claim 30, wherein the agent is a toxin.
33. The method of claim 29, wherein the imaging agent is a radioisotope.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.